<SEC-DOCUMENT>0000912282-14-000432.txt : 20140723
<SEC-HEADER>0000912282-14-000432.hdr.sgml : 20140723
<ACCEPTANCE-DATETIME>20140723120118
ACCESSION NUMBER:		0000912282-14-000432
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140722
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140723
DATE AS OF CHANGE:		20140723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AntriaBio, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54495
		FILM NUMBER:		14988229

	BUSINESS ADDRESS:	
		STREET 1:		890 SANTA CRUZ AVENUE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		890 SANTA CRUZ AVENUE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>antribio8k_07182014.htm
<TEXT>
<html>
<head>
    <title>antribio8k_07182014.htm</title>
    <!--Licensed to: sand-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): <font style="FONT-WEIGHT: bold">July 18, 2014</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ANTRIABIO, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Name of registrant in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Delaware</font></font></div>
</td>
<td valign="top" width="16%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">000-54495</font></font></div>
</td>
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">27-3440894</font></font></div>
</td>
</tr><tr>
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or jurisdiction</font></div>
</td>
<td valign="top" width="16%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File</font></div>
</td>
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of incorporation or</font></div>
</td>
<td valign="top" width="16%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number)</font></div>
</td>
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">organization)&#160;</font></div>
</td>
<td valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">890 Santa Cruz</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Menlo Park, CA 94025</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">(650) 241-9330</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Registrant's telephone number)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Not Applicable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="BM101"><!--EFPlaceholder--></a>Item 5.02 Departure of Directors or Certain Officers; Election of Officers; Appointment of Certain Officers:&#160;&#160;Compensatory Arrangements of Certain Officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Appointment of Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 18, 2014, the Board of Directors (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Board</font>&#8221;) of AntriaBio, Inc. (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;) increased its size from three directors to seven directors and appointed Barry Sherman, M.D. to the Board.&#160;&#160;&#160;Dr. Sherman brings more than 30 years of experience in the biopharmaceutical industry to AntriaBio&#8217;s Board of Directors. Notably, Dr. Sherman was the first Chief Medical Officer of Genentech in the mid 1990s following his role directing Genentech&#8217;s clinical research and medical affairs teams in the late 1980s. Dr. Sherman has also served as President and CEO of StemPar Sciences, President and CEO of Anergen Inc., a founder of Pain Therapeutics, and the Executive Vice President and Co-Founder of BiPar Sciences.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has not entered into any agreement, arrangement or understanding with Dr. Sherman regarding his appointment to the Company&#8217;s Board. Dr. Sherman will be granted stock options to purchase up to 75,000 shares of common stock under the Company&#8217;s 2014 Stock and Inventive Plan (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Plan</font>&#8221;).&#160;&#160;The options will vest monthly over four years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Appointment of Chief Accounting Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 18, 2014, Morgan Fields was formally elected as the Chief Accounting Officer by the Board.&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Ms. Fields, age 34, has served as the Company&#8217;s Controller since October 2012.&#160;&#160;&#160;Prior to joining AntriaBio Inc. Ms. Fields was an Assurance Director with McGladrey LLP and had been with McGladrey LLP since 2003.&#160;&#160;&#160;Ms. Fields is a Certified Public Accountant.&#160;&#160;&#160;Ms. Fields received her Bachelor&#8217;s degree in accounting as well as her Masters in Accounting fromthe University of Northern Iowa.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result of Ms. Fields&#8217; promotion, her base salary was increased to $130,000 annually.&#160;&#160;In addition, she received a stock option for the option to purchase up 30,000 shares of common stock under the Plan.&#160;&#160;The options will vest monthly over four years, assuming continued employment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are no arrangements or understandings between Ms. Fields and any other person pursuant to which he was selected to serve in the roles described above. Ms. Fields does not have any familial relationship with any director or executive officer of the Company, and there are no transactions in which Ms. Fields has an interest requiring disclosure under Item 404(a) of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Resignation of Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 21, 2014, Steve R. Howe resigned from his position as a member of the Board. Mr. Howe&#8217;s resignation was not the result of any disagreements with the Company on any matters relating to the Company&#8217;s operations, policies or practices. The Company would like to thank Mr. Howe for his dedicated service.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 7.01. Regulation FD Disclosure.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 23, 2014, the Company issued the press release attached hereto as Exhibit 99.1 announcing the appointment of Dr. Sherman to the Board.&#160;&#160;In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of the Securities Exchange Act of 1934, as amended.&#160;&#160;The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits</font></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="11%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">EXHIBIT</font></font></td>
<td width="89%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">DESCRIPTION</font></font></td>
</tr><tr>
<td width="11%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></td>
<td width="89%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release, dated July 23, 2014*</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* The exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div id="FTR">
<div id="GLFTR" style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ANTRIABIO, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DATE:&#160;&#160;July 23, 2014</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="TEXT-DECORATION: underline">/s/ Nevan Elam<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nevan Elam</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div><br>
&#160;</div>

<div>&#160;</div>

<div>
<div id="FTR">
<div id="GLFTR" style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%; HEIGHT: 16px"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="11%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">EXHIBIT</font></font></td>
<td width="89%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">DESCRIPTION</font></font></td>
</tr><tr>
<td width="11%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></td>
<td width="89%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release, dated July 23, 2014*</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* The exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div id="FTR">
<div id="GLFTR" style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%; HEIGHT: 16px"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE, DATED JULY 23, 2014
<TEXT>
<html>
<head>
    <title>ex99_1.htm</title>
    <!--Licensed to: sand-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><br>
<font style="FONT-WEIGHT: bold">EXHIBIT 99.1</font></div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><font style="BACKGROUND-COLOR: #ffff00; DISPLAY: inline"><img src="antriabiologo.jpg" alt=""></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">AntriaBio Appoints Barry Sherman, M.D. to its Board of Directors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">MENLO PARK, CA &#8211; July 14, 2014 &#8211; </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">AntriaBio, Inc.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced today the appointment of Barry Sherman, M.D. to its Board of Directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Sherman joins AntriaBio&#8217;s Board as the company prepares for the clinical development of its lead product candidate, <font style="DISPLAY: inline; TEXT-DECORATION: underline">AB101</font>, a once-weekly, proprietary, microsphere formulation of insulin with the potential to transform the treatment paradigm in the $10 billion basal insulin market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;Dr. Sherman is a true pioneer of the biotechnology industry. I am thrilled to have him join our Board of Directors and I look forward to leveraging his immeasurable business and scientific expertise,&#8221; commented Nevan Elam, Chairman and Chief Executive Officer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Sherman brings more than 30 years of experience in the biopharmaceutical industry to AntriaBio&#8217;s Board of Directors. Notably, Dr. Sherman was the first Chief Medical Officer of Genentech in the mid 1990s following his role directing Genentech&#8217;s clinical research and medical affairs teams in the late 1980s. He has also served as President and CEO of StemPar Sciences, President and CEO of Anergen Inc., a founder of Pain Therapeutics, and the Executive Vice President and Co-Founder of BiPar Sciences.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Sherman stated, &#8220;I am excited to join AntriaBio&#8217;s Board of Directors given the company&#8217;s unique opportunity to leverage its formulation platform to develop extended release novel therapeutics such as AB101. I look forward to working closely with the management team on AB101 as well as additional potential product pipeline opportunities.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Prior to joining Genentech in 1985, Dr. Sherman was Professor of Medicine and Endocrinology at the University of Iowa College of Medicine, where he served as Associate Chairman of the Department of Internal Medicine and Director of the National Institutes of Health-sponsored Clinical Research Center. Dr. Sherman is a graduate of the University of Michigan where he received both his A.B. and M.D. degrees with honors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About AntriaBio, Inc.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AntriaBio is a biopharmaceutical company focused on developing novel therapeutics to improve significantly the standard of care for patients. AntriaBio's development strategy combines FDA approved pharmaceuticals with its proprietary formulation and manufacturing capabilities. AntriaBio's lead product candidate is&#160;AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit:&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">www.antriabio.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain</font></div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><img src="antriabiologo.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AntriaBio, Inc. Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Jenene Thomas</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investor Relations and Corporate Communications Advisor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Jenene Thomas Communications, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(908) 938-1475</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jenene@jenenethomascommunications.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Source: AntriaBio Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"># # #</font></div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>antriabiologo.jpg
<TEXT>
begin 644 antriabiologo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`#0`
M\`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\KD_BO\;_``S\%-'%YXBU.*S$@)BA4%YY_P#=0<GZ\`=R*I?M
M$?&ZR^`?PSN]<N52:Z)\BRMRV/M$Q!(!_P!D`%C[`]\5^:'CWXA:Q\6O&$^J
M:U?/=7M](,R2OM2,$\`=E09X`X`KX#C/C:.46PV'BIUI*]GM%=WW;Z+3NWM?
MP<YSI82U.FKS?W+U_P`CZR\5_P#!5&PMKHIHOA:>YA5B-]W="-B/7:JL/_'J
M3PM_P52LKB["ZQX5FMX20-]K=B1P,]=K*!_X]7Q_XI\):GX(UE]/U:RN+"[0
M!]DJXWJ1D.IZ,I'(8$@BLZOR:IX@\00K-SJV:>L>6-EY6M?\;GRDL_S!3UG;
MRLO\C]6?A+\=O"_QMTHW7A[4X[IXQF6W<>7<0?[R'G&>XR#V-=?7Y(^`/B!J
MWPR\46FL:->2V=]:/N1T/4=P1T(/0@\'O7Z7?LU?'>T_:"^&=MK$2QP7\)^S
MW]NIR(9@`21WVL""/KCJ#7ZOP9QQ'-[X;$14:R5]-I+JUV:ZKYKK;ZK)L[6+
M_=U%::^Y^G^1Z!1117Z">^%%%%`!1110`4444`%%<6OQKL;G]H!OA[:V\MUJ
M-KH?]N7]PCKY=A&TPB@C<==\I$K#VA8]Q7:4VK"3N%%%%(845\-_M#?MN?'?
MP!_P4V\*?#?PYX'%]\/-1GLHI9SITDAO;>;;]HNA<`X3R<R<#@>4=P.X5]R5
M<X.*3?4B%12;2Z!1114%D=W>0V%L\\\L<$,0W/)(P54'J2>`*P4^+OA675+>
MQC\1Z)->7;B.&&.]C>21CT``))-;M]8P:E:26]S##<6\HP\<J!T<>A!X(KXR
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M/4?B%XIO=:U:=;G4=0D,DTBQK&I/LJ@`"O;/^";>B2ZE^T=!<HK&/3[&XF<X
MX&5\O^<@KY'A*HZ>>X=T&W[Z6UFT]'=7=M+W5WZGDY5)QQU/D_F_#_AC]"*Q
MOB!\0]"^%/A"^\0>)=6L-#T738S+<WEY,(HHE]R>YZ`#DG`&36S7Y;?%3XB3
M_P#!5?\`X*IV/PK%S+-\(?AA<376I6D3GR=5DMCME>3'#!IBL*^B%B,%C7]7
M4J?,W?9;GZ;5J<J5MWL?9W@#_@I#\-OB+J&G&T3Q?8Z'K-TMEIWB+4?#EW9Z
M)?3.VV-$NI$"?.WRJ6P&/`.>*].\0_&WP]X9^+WAWP+<74C^)O$]M<WMI:Q1
MF0QP0*#)-*1_JTR0JEN&8X'.:Y?]LKPYHTG[&'Q)T^]M[:#2+3PI?%(U0)';
M>3;.\10#A2C(A7'0J,5\6_\`!"N^\5?M,_$[XE_''QW?RZOK<T%KX7L[F1-H
MCC15DD1!T5<+`2!U+,3R2:I4XN+GV)=22DH/5L^M_P!H+_@H7\-_V7[BY7QG
M+XITRWM91;F[_P"$<OGLY)2"0B3B+RW;`)^5CTK7G_;?^&FG_L_:-\3K_P`1
M)IOA3Q$F[39+F"1+J^;+`1Q0`&1W.T_*JDX&>G-?'7_!QM\<(_#OP(\&_#Z&
M>..Y\5:J=1N003MM[9<#..QDE4^O[NO>_P!@K]F"'PA\//#'COQI8QPZSI>@
MP:=X<L+I1L\)Z4D2X"J>%NI]OFSR?>RP0$*F"W3BJ:F^HE5DZC@NAW'[+?\`
MP4&^%_[8.O:MI'@S6KF76M%4R76G7]G)9W2H&"EPC@;E#$`XY4D9`S6)^W+_
M`,%$_#W[$W@C4K^]\.^+=?U&U54B6UTBX33EE<#RQ+>,@A122/NLS=0`3Q7Q
M3_P2<EF_::_X*Q_&+XM:;$;?PY:B]*,@PDOVF<);J2.K-'$[GW7/I78?\'%'
MQ0N]5\,_#'X4Z2\DNH>*=5;49K=,YE"8@MT/J&DE?CUC%6J,?:J!G[>7L7,Z
MC_@E)^T:NH>!?&GQ3^(%MXNN_&7Q3ULWCR67A74;NWCLH$\JWBBDBA=?+4^8
M``QP`,\YKZ8^.'_!0'X=_LZZ<][XL;Q9INGQQQ2/>'PS?FU4RJK(AE\K8'.X
M#;G(;(.""*[[X`_"FV^!GP1\)^#K0((/#>E6^GY7H[1Q@,W_``)LG\:^,O\`
M@X;^.">`_P!CS3?!L,BB\\=ZM$DB;L'[-;$3.?\`OZ(!^)J$E4J6MN6W*G2O
M?8^AM6_X*1_"'0/V<M*^*=]XD>S\*ZZ\L6F^;:2+>7[QLRNL<&-[%2IR<8`Y
M)`I/AE_P4<^%WQB^$S^,_#=[X@UG28;J2SN(['0;R[NK65%#D2111N4!4@AC
M\ISP<@@>-_\`!/\`_85L?&7[(%G<^/K6Y-SXJ\)'P[I5MNV2Z!H\\9+>5_<G
MN7=IY'QGYHT/"8/;_!_]FWP;_P`$C/V.OB#J.BZCJ>IQ6%M<Z]=W>H%/-N)D
MAQ%$%4!0,A5`[ECZT2A35TKWN.,ZCLW:UCM/V8_^"A_PM_:_\=:OX<\":O?Z
MEJ>AVOVRZ6?3IK5$CWJF09%&3N8#'6O8/%7BO3/`WAR]UC6M0L]*TK3HFGNK
MNZE6*&W0=69FP`/K7YO_`/!NC\*[R\\*?$OXI:HKO=^*=2338)6``D$>9IF'
MLSRH#[I69^W9\5]2_P""AW_!2'PQ^S=HU[<V_@/PU?K-XE-NY3[=+"AEN-Q&
M,K&@\M1VD+'GY<.5%>T<8O1;DQKOV:E):O8^O?#G_!3SX6>*Y?M5E)XMD\+B
MZ^QGQ4WAR\30%DW;/FO&0(J[\+N;"@D9('->K^._CCX<^'?C;PCX<U&\<ZWX
MXNY+32+2",RR3F.)II)"!]V-$7+.>!E1U(IGCCP#X<TKX":SX9;3[.R\*P:'
M/8-9QQ!8(;00,A0+TVA,U^;7_!#K5O%O[5W[3&O?$CQEJ=UK-O\`#CPW:^%]
M%:7`2V5QL4*/[WE0N6;JQE)).:F-.,HN2T2*E4E&2B]6_P"F?I-^T!XZ_P"%
M;?!CQ)K*L%FM+)Q!DXS*XV1C_OMEKYY_83UC1O@Q\+;K6]6:XDU;Q;=$6-G:
M6TES>W<,&1N6-`6*AVD&XX'R]:W?^"F?C=K'X=:)X9MV+76NWAF:,#<S1Q`#
MI_ONI'^[7I_[,'P*A^"WPZL8[D?:-?N;:,7MP_S.@`RL"GLB9Q@=3ENIK\YQ
M#K8WB;EH6MAX;O51E/RNKMQT2NN[VL_(J<];,K0VIQW?1R_6W]=#6^%?[0/A
M?XQW=Y:Z->R&_P!/)^T6EQ$T,\8!P3M/4`\'&<'@XK-^(/[5'A#X7SF/6Y=7
MLOWC1*[Z5<".5E/(5B@5NF>#TYKYQ@U%O#G_``4YD2P<1QWFH>5.JGAA):Y<
M'_@1)^M='_P4E\3S^(=<\'^"+!E>[OIOM;1AN=S-Y461[GS!^-<]3BS&1RK$
MXGW?:T:CI[.TW=)67-=7OKJ]C.6;55A:E33FA)QVT>JMUTW/J#PAXKL_'/A>
MPUC3G>2QU*%;B!G0HS(PR"0>1Q6)\2?C;X=^%36\.JWCM?WF!;6%K$UQ=W!)
MP-L2`MUXR<#/>LKXD>-;+]F7]G]KS;'(N@V$5E9Q,<">4*(XU/MG!/L":\K_
M`&#?`EUXT&J?$WQ*[ZAK>LW#Q6<LW)AC7AW4?PDGY!CH$P,`XKZ#&9Q7CB:.
M64$G7G'FDW\,(K=VO=W>D5?U??T*V,J*I##02YVKM]$NK^_1(]@M/COI">(K
M#2M5M=6\.WNK`FR74[<0I=$$`HKJS*'R1\I(/(]17:U\X_\`!3.:*U^#>ARD
M[;E-:3R6!*L/W,N<$<CM^GM7LWP1\3W'C3X/^&-6NV+W6H:9!-,V<EG,8R?Q
M/-;8#-:DLRK9;5U<(QDGM=/=-=T^VZ>VFMT,5)XF>&GKRI-/R?<\L_;^^`4_
MQ=^&,6JZ9"9]7\.[I5C49:>`X\Q1ZD8##V#`<FOSV2-([E5G$@C5AO"8#8SS
MC/&<5^PE?-'[37_!/BP^)>H7&M^$Y;;2-6G)>:TD!6UN&/)92`?+8GD\$'VY
M-?#<?<$5L;5_M++U>=O>CWMLUYVT:ZV5M=_$S[))UI?6<.KOJN_FCY)\?_M`
M:UXQ\+VGANR*Z#X3T]!';Z39N5C<?WYFZRN3DDGC)/%<(!@``8`KTOQ1^R#\
M1O"=Z\-SX5U:4*V!);0FYC?W#1[A^>#2>&OV1/B-XJO$AMO"FKQAFP9+B`V\
M:^Y:3:/US7Y'BLOS;$5K5J51SVMRRT2V25M$NB6B/DJN'Q52=IPDWML_N/-E
M4NP`!)-?H%_P3U^`5Q\+/AS/KNJ0M#JOB,*Z1."&AMQRN0>A8G=]`G?-8O[-
M?_!.VQ\`ZC;ZUXQFM]6U"`AX;&,;K:)NQ<G[Y'IC;Z[J^GZ_6N`>"*^#JK,L
MP7+-+W8]5?=OSMHETN[ZGU>0Y).C/ZSB%9]%V\V9GC?49M(\%ZO=VQVW%K93
M2Q'&<,L;$?J*_*W_`(-LM%.N_$GXP^);IM]_';6%N6(^8^?+<2.?Q,*_E7ZR
M.BRHRLH96&"",@CTKX3^"/\`P3V^+'[!W[2'C76_@Y=>!]=\#>/<-+IOB*YN
M+6;265V>+!B1O,6/S)5'(+*0#@C<?V.E)<DH]78^EJP?/&5M%<G_`."]'[5U
MI\%/V2)O!%I=1_\`"2?$9Q9I`I!>.R1@T\A&<A6PL8]=[?W37:?\$R/#6B?L
M>_L$_"K2M;F:RU;QW<)<)#Y3//=WEZ3*B!5!/R0!=S=%6(DD`5YS^W7_`,$E
M/%G[4/P32Y3Q7I6M_%FZUB+4]3U._B:ULY8$ADB2QM57>;>WB\PLH.XNV]F)
M9LCVK]EO]E;QWX5GTWQ?\5=?T3Q+XX\/:,-'\.Z?ID+P:/X>B\M5=HPWS//-
MM423$#"C:H"Y!MN'LE%/KJ0HS]JY-=-#XM^,&FQ?M_\`_!>#2_#5P#>^%?AF
MB)<QD[HBEF#-*"!V>ZD$1]1BOKK_`(+&?M*']FW]ACQ/+9SF#6_%@'A[3BK;
M65IU;S7'?*PK(01_%MKD?^"7O_!-WQ=^R/\`%KXB>._B#JVA:SXE\9$".736
M=U3S)GFN&)=%(W/Y>`,_=-=3_P`%:OV#-?\`V]/@?HND>&-5TW3M;\.ZG]OA
MCORRP72M&49"Z@E&&00<$<$=\TY3@ZD5?1"C":IRDE[S.,_X)!_#K1/V-?V#
M_">L>(Y19ZS\5=4@ND01-)/<R73".SA55!8_N@)#QA0SL<`$UX9JZC]M'_@X
M$AM)`)M"^%`!VL"R[K%-QXZ`_;)<?\!KZ\_9#_9'\;^&+CPQXD^,7B'1_$/B
M/P9I2:/X<TO1X&BTO0HQ$(Y+@;N9;J1%"&0@!5RJ@!C7A7Q"_P"":/QL^#W[
M>/B+XQ_!#Q3X/C7Q?+<2WMKKXEQ!]H97FC950^8GF#>I!4C`';)<9QYY.^K0
MI0ER15M$T?</BKXO:3X3^)'ACPG-]IN-<\5?:'M8+=`YAA@CWRW$O/R1`F--
MW=Y4`Z\?F+^W=8K^WO\`\%H_`_PK!-UX<\%I##J**,KA5-Y>9_WD"1?517Z#
M_LV?LYZO\,;_`%7Q9XX\1KXU^)/B*)(+_5%MQ;6MG;(2T=E:1#_50*Q+'^*1
MB6;G`'@G_!/W_@F_XR^`/[6OQ#^+?Q#U70=5UKQ:)Q9KI\LLOV<W%QYLN=Z+
M@`*BC&>,U%*487E?6WXFE6,IVC;1O\#[5AA2VA2.-%CCC4*JJ,!0!P`.PKX*
M_P"#A3XZ-\._V/M-\(6TS1WOCW54A=5;:3;6^)9#[CS/(!^M?>]?&/\`P5V_
MX)Q>*?VZK'P3JG@S5]*LM<\'2W`^RZF[I;W,<QB.X,JMAE,0X(P0W7@9B@XJ
MHG(O$*3IM1W/0_V'?#&A?L9_LD?!_P`":E*EMKWB2!5BM8HR\UW?31O=S\*"
M0L8+!G/RJ%7)&1GX5_X(<V#>-O\`@I+\8?$NIAGU2WL[]_WGS,CSW\9<Y]?E
M(_$U^@G[,W[.7BS0?$H\>?%?7-*\2_$-[`:7:)I=NT&E>'K3*L\-JC<EY&56
MDE;YFVJHPJX/AFD?\$]/B5^R=^VOXH^*/P6F\':MH/CI)EU30=?N9K/[(\LB
MRLT<D<;Y`E&Y>!@,RD'AJTC->\F]68RIR]QVT1VG_!93]K"T_9C_`&,-?M(;
MI(_$OCB%]#TN$/B3;(N+B;']U(BW/]YT'>N'_P"".GAW1/V2/^"<VA^)_$4I
MLI_'VKB]^6-I9KJ2XE6UM8D1069F"*0H!X8GIDU/^V?_`,$O/%W[6GP*UNZU
MGQ1I&J?%O4KNVN+>=XWM]'TNTBW_`/$NM5PSQQ$N7:1@7DD12V`%"]S^Q=^Q
MCX]\&:5X)N_C%K^A:W=?#?3TTWPMHNC0LFGZ85B\DWDK,`9[HQ?(&("H&<J-
MS$@O!4N6_74=INKS-=-"E^T?"?&/[?G@72+Q0UE:I:2JK_=;$LDA'XE0/>OK
M&]O(M.LYKB>1(H($,DCL<*B@9)/L!7E'[17[.=W\3?$NA>*O#U];:;XJ\..K
MV[7"DP7*JV]4?'(PV>QR&8>A%?QOX&^)'QRT<Z%K)T+PAH5P`NH/873WMU>+
MW1=R(J*>^<Y[Y&0?@<%3Q.7XG&R]E*<JL^:#6TERI)-[1Y7OS6TVN<%"-7#U
M:SY')R=U;9Z;-]+>?R/'OV0/#,_QJ_:G\2_$22)ETJRN)Y+=F4C?+)E47GNL
M9.?3Y?6G>`T/Q]_X*&:CJK;I=-\+L[(<?+B`"*,?C(0_YU]3_#SX>:3\+/"5
MIHFB6JVEA:+A1U:1CU=S_$Q/))KY]^'O[(?C_P"&/Q,\12:)XCTC3]"\0EUF
MOA&TE]%$S;OW:D;5DQQN)(!YQTKPZ_#N*PE'!T>1U?WKJU>6VL[76[7NWTN^
MUW8XIY=5I0HPY>;WG*=N_3?I<;_P43\41^+O@E!_9,QN+33O$!LKY@K!!(D,
MF5!Z-@D@D9`((Z@U[-^S+HB^'OV?/!UJH`(TJ"5_=Y$$C'_OIC3O%7P!T#Q/
M\&)/`_DO;:4(!'"Z_-+#(IW+-D_>??\`,2?O$G/4USG@K0?B3\._AQ9^%K*R
M\-WT^EQ"SL]7GO9$B$*C",\`0L65<#`;!QUKWJ6"KX;.)YC7BY*I34?=3=I)
MZQMO9Z6;LM'>QW0HU*6,EB*BOS12TULT]O\`@_D>.?\`!0'6;GXK_%OPG\/=
M%475["_FS1J,A99<;=WH%0%CZ*^:^J_!GAF#P7X1TO1[;'D:9:QVJ'&,A%"Y
M_'&:X+X'?LT6?PKUJ^\0ZI>OX@\7ZL2UUJ4R!0F?O+$O\()ZGJ1@<#BO3ZZL
MARJO3Q-?,\8K5*S7N[\L(Z15UI?K*VE]C7`86<:E3$UE:4^G9+9>O<****^H
M/4"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
/`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
